Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical Mass Spectrometry (Del Mar, Calif.)|August 28, 2024
Urine analysis of 28 designer benzodiazepines by liquid chromatography-high-resolution mass spectrometryMadeleine Pettersson Bergstrand, Olof Beck, Anders Helander
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 5, 2016
Development and application of a multi-component LC-MS/MS method for determination of designer benzodiazepines in urineMadeleine Pettersson Bergstrand, Anders Helander, Olof Beck
Drug Testing and Analysis|July 2, 2016
Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assaysMadeleine Pettersson Bergstrand, Anders Helander, Therese Hansson, et al.
Clinical Toxicology (Philadelphia, Pa.)|October 24, 2018
Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA projectMatilda Bäckberg, Madeleine Pettersson Bergstrand, Olof Beck, et al.
Drug Testing and Analysis|July 12, 2018
In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferasesMadeleine Pettersson Bergstrand, Lilian H J Richter, Hans H Maurer, et al.
Therapeutic Drug Monitoring|June 12, 2024
Quantification of Efavirenz Hydroxymetabolites in Human Plasma Using LC-HRMS/MSMadeleine Pettersson Bergstrand, Sandra Soeria-Atmadja, Victoria Barclay, et al.
Analytical and Bioanalytical Chemistry|January 9, 2019
In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening proceduresLea Wagmann, Lilian H J Richter, Tobias Kehl, et al.
Pageof 2